Overview The News Click Therapeutics has received FDA 510(k) clearance for Motivista (CT-155), a smartphone-based prescription digital therapeutic indicated for treating negative symptoms of schizophr...
Conversations Shaping Tomorrow's Healthcare
Overview The News Click Therapeutics has received FDA 510(k) clearance for Motivista (CT-155), a smartphone-based prescription digital therapeutic indicated for treating negative symptoms of schizophr...